Promising Q3 2022
With the outlicensing of our HSV-2 vaccine program to Eurocine [...]
Successful expression of kappa casein
Redbiotec has successfully expressed the kappa casein, an essential protein [...]
Expansion of platform – adding bifidobacteria and yeast
Redbiotec has expanded its platform by adding further microorganisms. In [...]
BIO Digital 2020
Date: June 8-12, 2020 At a time when collaboration [...]
Recent interview with Mergermarket, Acuris
As Redbiotec prepares for a Series A financing round to [...]
Analysis of Redbiotec by In Vivo (Informa Pharma Intelligence)
Redbiotec Pivots Toward HSV-2 Therapies And Therapeutic Bacteria Redbiotec has [...]
Redbiotec Signs Collaboration Agreement with Large-Cap Pharma to Develop Targeted Living Medicines
Redbiotec AG has entered into a research collaboration and exclusive [...]
Swiss Nordic Bio Conference
Date: Feb 6, 2020 Location: Zürich We will attend this [...]
Outlook 2020
We thank you for your trust and support in 2019 [...]
Gene therapy expert Dr. Michele Calos joins the Scientific Advisory Board of Redbiotec
Redbiotec AG, a pioneer in living medicines, further expands its [...]